LLY

1,007.46

+0.3%↑

JNJ

230.57

+0.93%↑

ABBV

211.37

+2.41%↑

UNH

400.75

+0.42%↑

AZN

185.67

+0.03%↑

LLY

1,007.46

+0.3%↑

JNJ

230.57

+0.93%↑

ABBV

211.37

+2.41%↑

UNH

400.75

+0.42%↑

AZN

185.67

+0.03%↑

LLY

1,007.46

+0.3%↑

JNJ

230.57

+0.93%↑

ABBV

211.37

+2.41%↑

UNH

400.75

+0.42%↑

AZN

185.67

+0.03%↑

LLY

1,007.46

+0.3%↑

JNJ

230.57

+0.93%↑

ABBV

211.37

+2.41%↑

UNH

400.75

+0.42%↑

AZN

185.67

+0.03%↑

LLY

1,007.46

+0.3%↑

JNJ

230.57

+0.93%↑

ABBV

211.37

+2.41%↑

UNH

400.75

+0.42%↑

AZN

185.67

+0.03%↑

Home・Akciju saraksts・iRhythm Technologies Inc

iRhythm Technologies Inc

Atvērts

SektorsVeselības aprūpe

114.46 0.06

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

111.74

Max

115.81

Galvenie mērījumi
By Trading Economics
Ienākumi	-20M -14M
Pārdošana	-9.5M 199M
EPS	-0.35
Peļņas marža	-6.988
Darbinieki	2,400
EBITDA	-21M -5.3M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+52.06% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 30. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-299M 3.8B
Iepriekšējā atvēršanas cena	114.4
Iepriekšējā slēgšanas cena	114.46

Ziņu noskaņojums

By Acuity

50%

162 / 346 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

104.78 / 137.91 Atbalsts un pretestība

iRhythm Technologies Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. maijs 22:54 UTC

Peļņas

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

2026. g. 13. maijs 23:51 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 13. maijs 23:51 UTC

Tirgus saruna

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

2026. g. 13. maijs 23:45 UTC

Tirgus saruna

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

2026. g. 13. maijs 23:45 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 13. maijs 23:17 UTC

Peļņas

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

2026. g. 13. maijs 23:16 UTC

Peļņas

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

2026. g. 13. maijs 23:15 UTC

Peļņas

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

2026. g. 13. maijs 23:14 UTC

Peļņas

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

2026. g. 13. maijs 23:02 UTC

Tirgus saruna

Peļņas

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

2026. g. 13. maijs 22:59 UTC

Tirgus saruna

Peļņas

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

2026. g. 13. maijs 22:24 UTC

Peļņas

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

2026. g. 13. maijs 22:23 UTC

Peļņas

Xero FY International Organic Revenue Growth 25%>XRO.AU

2026. g. 13. maijs 22:23 UTC

Peļņas

Xero FY International Revenue Growth 47%>XRO.AU

2026. g. 13. maijs 22:22 UTC

Peļņas

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

2026. g. 13. maijs 22:19 UTC

Peļņas

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

2026. g. 13. maijs 22:19 UTC

Peļņas

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

2026. g. 13. maijs 22:18 UTC

Peļņas

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

2026. g. 13. maijs 22:16 UTC

Peļņas

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

2026. g. 13. maijs 22:15 UTC

Peļņas

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

2026. g. 13. maijs 22:15 UTC

Peļņas

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

2026. g. 13. maijs 22:13 UTC

Peļņas

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

2026. g. 13. maijs 22:12 UTC

Peļņas

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

2026. g. 13. maijs 22:11 UTC

Peļņas

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

2026. g. 13. maijs 22:11 UTC

Peļņas

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

2026. g. 13. maijs 22:10 UTC

Peļņas

Xero Did Not Declare a Dividend>XRO.AU

2026. g. 13. maijs 22:10 UTC

Peļņas

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

2026. g. 13. maijs 22:09 UTC

Peļņas

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

2026. g. 13. maijs 22:00 UTC

Peļņas

Cisco to Shed Jobs for All-In AI Push -- Update

2026. g. 13. maijs 21:11 UTC

Peļņas

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

iRhythm Technologies Inc Prognoze

Cenas mērķis

By TipRanks

52.06% augšup

Prognoze 12 mēnešiem

Vidējais 179.9 USD 52.06%

Augstākais 255 USD

Zemākais 147 USD

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi iRhythm Technologies Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

13 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 13 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam iRhythm Technologies Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

104.78 / 137.91Atbalsts un pretestība

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Noskaņojums

By Acuity

162 / 346 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par iRhythm Technologies Inc

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.